Cargando…

Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis

INTRODUCTION: Liraglutide is a glucagon-like peptide-1 analogue used to treat type 2 diabetes mellitus (T2DM). To date, limited long-term data (> 2 years) exist comparing real-world diabetes-related effectiveness and costs for liraglutide versus insulin treatment. METHODS: This retrospective clai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilke, Thomas, Mueller, Sabrina, Fuchs, Andreas, Kaltoft, Margit S., Kipper, Stefan, Cel, Malgorzata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509007/ https://www.ncbi.nlm.nih.gov/pubmed/32876862 http://dx.doi.org/10.1007/s13300-020-00903-0

Ejemplares similares

Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus
por: Bruinstroop, Eveline, et al.
Publicado: (2018)

Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage
por: Wilke, Thomas, et al.
Publicado: (2019)

Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i
por: Blonde, Lawrence, et al.
Publicado: (2021)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
por: Lind, Marcus, et al.
Publicado: (2015)

Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data
por: Bokemeyer, Bernd, et al.
Publicado: (2022)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

Is there an association between liraglutide use and female breast cancer in a real-world setting?
por: Funch, Donnie, et al.
Publicado: (2018)

Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database
por: Uzoigwe, Chioma, et al.
Publicado: (2022)

Trial design and baseline data for LIRA‐PRIME: A randomized trial investigating the efficacy of liraglutide in controlling glycaemia in type 2 diabetes in a primary care setting
por: Unger, Jeff, et al.
Publicado: (2019)

Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
por: Huang, Wan-Chun, et al.
Publicado: (2021)

Non-diabetic use of liraglutide
por: Verma, Abhyudaya
Publicado: (2012)

Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
por: Minze, Molly G, et al.
Publicado: (2016)

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
por: Mader, Julia K., et al.
Publicado: (2016)

Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus
por: Wilke, Thomas, et al.
Publicado: (2015)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Blonde, Lawrence, et al.
Publicado: (2019)

Liraglutide Treatment in a Patient With HIV and Uncontrolled Insulin-Treated Type 2 Diabetes
por: Diamant, Michaela, et al.
Publicado: (2012)

Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin‐secreting capacity
por: Kozawa, Junji, et al.
Publicado: (2012)

Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
por: Matsumoto, Shinobu, et al.
Publicado: (2013)

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
por: Tonoike, Mie, et al.
Publicado: (2018)

The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis
por: Zhang, Jiudan, et al.
Publicado: (2021)

Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset
por: Mueller, Sabrina, et al.
Publicado: (2018)

Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA‐Ramadan): a randomized trial
por: Azar, S. T., et al.
Publicado: (2016)

Liraglutide in the management of type 2 diabetes
por: Wajcberg, Estela, et al.
Publicado: (2010)

Medication Adherence and Healthcare Costs in Chronically Ill Patients Using German Claims Data
por: Wendl, Johannes, et al.
Publicado: (2023)

Liver disease epidemiology and burden in patients with alterations in plasma protein metabolism: German retrospective insurance claims analysis
por: Picker, Nils, et al.
Publicado: (2023)

Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA‐PRIME)
por: Unger, Jeff, et al.
Publicado: (2021)

Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
por: Ericsson, Åsa, et al.
Publicado: (2017)

Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis
por: Wilke, Thomas, et al.
Publicado: (2015)

Poststroke epilepsy incidence, risk factors and treatment: German claims analysis
por: Hardtstock, Fränce, et al.
Publicado: (2021)

Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus
por: Bretón‐Romero, Rosa, et al.
Publicado: (2018)

Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial
por: Blonde, Lawrence, et al.
Publicado: (2020)

Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients
por: Müller, Sabrina, et al.
Publicado: (2017)

Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes
por: Harris, Stewart, et al.
Publicado: (2020)

Effect of Liraglutide on Type B Insulin Resistance Syndrome and Insulin Allergy in Type 2 Diabetes: A Case Report
por: Matsumoto, Yuko, et al.
Publicado: (2017)

Managing insulin resistance: role of liraglutide
por: Kalra, Sanjay, et al.
Publicado: (2010)

The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database
por: Eby, Elizabeth L., et al.
Publicado: (2020)

Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
por: Kocaata, Zeki, et al.
Publicado: (2022)

Real-World Treatment of Patients Newly Diagnosed with Chronic Obstructive Pulmonary Disease: A Retrospective German Claims Data Analysis
por: Buhl, Roland, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v9h5hcakoip295hns10h9kppn9